Elagolix — Discount Pricing

Other medications in Women's Health

• Emergency Contraception
• GnRH Agonist
• GnRH Antagonist
• Gonadotropins FSH
• Gonadotropins hCG
• Indomethacin (Tocolytic)
• Letrozole (Infertility)
• Levonorgestrel IUD

What Elagolix is approved for (FDA label)

ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ) [see D osage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 ) ] . ORILISSA is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis. ( 1 ) Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ). ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: December 19, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Elagolix (FDA label)

The 150 mg tablets are light pink, oblong, film-coated tablets with “EL 150” debossed on one side. Each tablet contains 155.2 mg of elagolix sodium equivalent to 150 mg of elagolix. The 200 mg tablets are light orange, oblong, film-coated tablets with “EL 200” debossed on one side. Each tablet contains 207.0 mg of elagolix sodium equivalent to 200 mg of elagolix. Oral tablets: 150 mg and 200 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: a86757b3-09c5-fd3b-1223-244e94f50a66. SPL document ID: 07f98869-6203-4e8c-b576-2ba8f0a159d7. Label effective date: December 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Elagolix (FDA label)

The following serious adverse reactions are discussed elsewhere in labeling: Bone loss [see Warnings and Precautions ( 5.1 )] Change in menstrual bleeding pattern and reduced ability to recognize pregnancy [see Warnings and Precautions ( 5.2 )] Suicidal ideation, suicidal behavior, and exacerbation of mood disorders [see Warnings and Precautions ( 5.3 )] Hepatic transaminase elevations [see Warnings and Precautions ( 5.4 )] Most common adverse reactions (>5%) in clinical trials included hot flushes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions and mood changes ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: a86757b3-09c5-fd3b-1223-244e94f50a66. SPL document ID: 07f98869-6203-4e8c-b576-2ba8f0a159d7. Label effective date: December 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Elagolix (FDA label)

ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 )] . Exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss. With known osteoporosis because of the risk of further bone loss [see Warnings and Precautions ( 5.1 )] With severe hepatic impairment [see Use in Specific Populations ( 8.7 ), Clinical Pharmacology ( 12.3 )] Taking inhibitors of organic anion transporting polypeptide (OATP)1B1 (a hepatic uptake transporter) that are known or expected to significantly increase elagolix plasma concentrations [see Drug Interactions ( 7.2 )] With known hypersensitivity reaction to ORILISSA or any of its inactive components.

Source: FDA prescribing information (DailyMed). Set ID: a86757b3-09c5-fd3b-1223-244e94f50a66. SPL document ID: 07f98869-6203-4e8c-b576-2ba8f0a159d7. Label effective date: December 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Elagolix (FDA label)

Bone Loss : Dose- and duration-dependent decreases in bone mineral density (BMD) that may not be completely reversible. Assess BMD in women with additional risk factors for bone loss ( 5.1 ) Reduced Ability to Recognize Pregnancy : ORILISSA may alter menstrual bleeding, which may reduce the ability to recognize pregnancy. Perform testing if pregnancy is suspected. Discontinue if pregnancy is confirmed ( 5.2 ) Suicidal Ideation and Mood Disorders : Advise patients to seek medical attention for suicidal ideation, suicidal behavior, new onset or worsening depression, anxiety, or other mood changes ( 5.3 ) Hepatic Transaminase Elevations : Dose-dependent elevations in serum alanine aminotransferase (ALT).

Source: FDA prescribing information (DailyMed). Set ID: a86757b3-09c5-fd3b-1223-244e94f50a66. SPL document ID: 07f98869-6203-4e8c-b576-2ba8f0a159d7. Label effective date: December 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Elagolix (FDA label)

See full prescribing information for a list of clinically important drug interactions ( 7 ). 7.1 Potential for ORILISSA to Affect Other Drugs Elagolix is: A weak to moderate inducer of cytochrome P450 (CYP) 3A. Co-administration with ORILISSA may decrease plasma concentrations of drugs that are substrates of CYP3A (see Table 7). A weak inhibitor of CYP 2C19. Co-administration with ORILISSA may increase plasma concentrations of drugs that are substrates of CYP2C19 (see Table 7). An inhibitor of efflux transporter P-glycoprotein (P-gp). Co-administration with ORILISSA may increase plasma concentrations of drugs that are substrates of P-gp (see Table 7).

Source: FDA prescribing information (DailyMed). Set ID: a86757b3-09c5-fd3b-1223-244e94f50a66. SPL document ID: 07f98869-6203-4e8c-b576-2ba8f0a159d7. Label effective date: December 19, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.